| MeSH term | MeSH ID | Detail |
|---|---|---|
| Myxoma | D009232 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- Clin. Infect. Dis. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ives DV et al. | Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. | 1995 | AIDS | pmid:7755914 |
| Fichtenbaum CJ et al. | Reply to 'Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis' by Holmberg and Moorman. | 2001 | AIDS | pmid:11546956 |
| Johnson RC et al. | Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. | 2002 | AIDS | pmid:12172103 |
| Heald AE et al. | Taste and smell complaints in HIV-infected patients. | 1998 | AIDS | pmid:9764787 |
| Hewitt RG et al. | Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. | 1999 | AIDS | pmid:10449290 |
| Preston SL et al. | Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. | 1998 | AIDS | pmid:9468380 |
| Bayoumi AM and Redelmeier DA | Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. | 1998 | AIDS | pmid:9727572 |
| Burman WJ et al. | Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. | 1998 | AIDS | pmid:9708410 |
| High-dose clarithromycin should be avoided. | 1996 | AIDS Alert | pmid:11363723 | |
| Physician's aggressive preventive therapy differs. | 1995 | AIDS Alert | pmid:11362774 | |
| New drug applications sought. | 1995 | AIDS Alert | pmid:11362777 | |
| Researchers find new drugs to fight MAC. | 1995 | AIDS Alert | pmid:11362925 | |
| Clarithromycin for MAC. | 1995 | AIDS Patient Care | pmid:11361361 | |
| Rosales CM et al. | AIDS presenting with cutaneous Kaposi's sarcoma and bacillary angiomatosis in the bone marrow mimicking Kaposi's sarcoma. | 2002 | AIDS Patient Care STDS | pmid:12542930 |
| Mah Ming JB and Gill MJ | Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. | 2003 | AIDS Patient Care STDS | pmid:12816614 |
| Monno R et al. | Chlamydia trachomatis and Mycobacterium tuberculosis lung infection in an HIV-positive homosexual man. | 2001 | AIDS Patient Care STDS | pmid:11788074 |
| Yangco BG et al. | Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? | 2014 | AIDS Patient Care STDS | pmid:24833016 |
| Desimone JA et al. | Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. | 2003 | AIDS Patient Care STDS | pmid:14746655 |
| NIAID study rules out high-dose clarithromycin for AIDS-related MAC. | 1996 | AIDS Patient Care STDS | pmid:11361534 | |
| New data suggest antibiotic clarithromycin is effective in prolonging life of AIDS patients. | 1996 | AIDS Patient Care STDS | pmid:11361575 | |
| Clarithromycin and MAC. | 1996 | AIDS Patient Care STDS | pmid:11361673 | |
| Different clarithromycin doses affect mortality. | 1997 | AIDS Patient Care STDS | pmid:11361754 | |
| Aboulafia DM | Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. | 2003 | AIDS Read | pmid:14524324 |
| Kahlon SS et al. | Mycobacterium-avium-intracellulare complex immune reconstitution inflammatory syndrome in HIV/AIDS presenting as osteomyelitis. | 2008 | AIDS Read | pmid:18975441 |
| Chu J et al. | Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. | 2011 | AIDS Res Ther | pmid:21388558 |
| Smibert OC et al. | Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. | 2017 | AIDS Res. Hum. Retroviruses | pmid:28791872 |
| Katelaris PH et al. | Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848659 |
| Ammon S et al. | Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848660 |
| Leiper K et al. | Open label trial of oral clarithromycin in active Crohn's disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848665 |
| Huang J et al. | Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. | 2013 | Aliment. Pharmacol. Ther. | pmid:24117692 |
| Molina-Infante J et al. | Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. | 2010 | Aliment. Pharmacol. Ther. | pmid:20180787 |
| Murakami K et al. | Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. | 2002 | Aliment. Pharmacol. Ther. | pmid:12390102 |
| Gisbert JP et al. | 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882246 |
| Nista EC et al. | Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882245 |
| Lehmann FS et al. | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735923 |
| Miwa H et al. | Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735925 |
| Malfertheiner P et al. | Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969088 |
| Hassan C et al. | Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969091 |
| Huang J and Hunt RH | The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383500 |
| Miwa H et al. | Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383502 |
| Ducóns JA et al. | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383507 |
| Wong BC et al. | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11736727 |
| Dobrilla G et al. | Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9692703 |
| Perri F et al. | Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535875 |
| Sheu BS et al. | Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. | 2005 | Aliment. Pharmacol. Ther. | pmid:15691303 |
| Broutet N et al. | Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492738 |
| Zullo A et al. | Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? | 2010 | Aliment. Pharmacol. Ther. | pmid:20518756 |
| Gisbert JP and Pajares JM | Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030945 |
| Laine L and Dhir V | Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030957 |
| Vallve M et al. | Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. | 2002 | Aliment. Pharmacol. Ther. | pmid:12030958 |